Long-term follow-up on tocilizumab treatment of AA amyloidosis secondary to polyarteritis nodosa

Amyloid A (AA) amyloidosis is a rare complication of chronic inflammatory diseases with a high mortality rate, with a 5-year survival rate of about 50% [1–3]. In the last decade, a monoclonal antib...